Biotechnology From Bench News
- ACT Announces First Patients Undergo Embryonic Stem Cell Transplantation Treatment for Stargardt's Disease and Macular ... Thursday, July 14, 2011 @ 10:10AMMARLBOROUGH, Mass., July 14, 2011 /PRNewswire/ -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced the dosing of the first patients in each of its two Phase 1/2 clinical trials for Stargardt's macular dystrophy and dry age-related macular degeneration (dry AMD) using retinal pigment epithelial (RPE) cells derived from human ...
- Combination therapy shows promise against HER2-positive metastatic breast cancer Monday, July 11, 2011 @ 1:48AMAdding Afinitor to Herceptin, the main treatment for HER2-positive metastatic breast cancer, helps some women with disease that has been resistant to previous Herceptin-based therapies, according to a study led by researchers at The University of Texas MD Anderson Cancer Center and published in the Journal of Clinical Oncology.
- Health care: Biotech synergies may change landscape Sunday, July 10, 2011 @ 1:19AMIn a modest office on the eighth floor of the Chase building, Emma Schwartz is shaping El Paso's future.
- Reagan v. Freud, science v. religion, population and Islam Friday, July 8, 2011 @ 8:53AMThere’s much to be learned from detective stories, including that the solution to any mystery usually lies in finding the right question to ask.
- UNR might hold part of key to treating muscular dystrophy Wednesday, July 6, 2011 @ 5:07PMDr. Dean Burkin stands in his Pharmacology lab at the University of Nevada, Reno. Burkin and his students have isolated a protein that protects muscle tissue from muscular dystrophy.
- Leading hopeful for New Jersey GOP declines Tuesday, July 5, 2011 @ 3:54AMJohn Crowley, 44, of Princton, who may run for U.S. Senate as a Republican, was the keynote speaker at a United Way fundraiser at the Parsippany Hilton on Friday, May 6, 2011.
- Pappas Ventures-backed CoLucid Pharmaceuticals Raises $3.5M - cbl Wednesday, June 29, 2011 @ 9:42AMBy Bill MurphyDURHAM, N.C. -- CoLucid Pharmaceuticals Inc. has raised $3.5 million of a $9.5 mi...
- CoLucid, Backed by Domain Associates and Care Capital, Raises $3.5M - cbl Wednesday, June 29, 2011 @ 9:22AMBy Bill MurphyPRINCETON, N.J. -- CoLucid Pharmaceuticals Inc. has raised $3.5 million of a $9.5 mill...
- Stem Cell Therapeutics Corp. Announces the Appointment of Mr. David Allan as Executive Chairman and Dr. Henry Friesen ... Tuesday, June 28, 2011 @ 6:11PMCALGARY, ALBERTA--(Marketwire - June 28, 2011) - Stem Cell Therapeutics Corp (TSX VENTURE:SSS) today announced the appointment of Mr. David Allan as Executive Chairman of the Corporation to take immediate effect. Mr. Allan will be a member of the Board of Directors of the Corporation and be responsible for the company's operations.
- Paul, Weiss Adds Two Prominent Patent Litigators Thursday, June 23, 2011 @ 4:57PMNEW YORK--(BUSINESS WIRE)--Paul, Weiss, Rifkind, Wharton & Garrison LLP announced today that Nicholas Groombridge and David J. Ball, Jr., two renowned patent litigators, have joined the firm's Litigation Department. Mr. Groombridge is resident in Paul, Weiss's New York office, and Mr. Ball is resident in its Washington, D.C. office. "We are thrilled to welcome two lawyers with such sterling ...
- Avila Therapeutics Presents Preclinical Data with AVL-292, its Btk Inhibitor, Demonstrating Suppression of Autoimmune ... Thursday, June 23, 2011 @ 7:14AMWASHINGTON & WALTHAM, Mass.--(BUSINESS WIRE)--Avila presented data at FOCIS 2011 meeting, AVL-292 rapidly reduced clinical arthritis scores as well as inflammation, joint damage and bone erosion in preclinical studies.
- Biotech firms want drug approval hastened Thursday, June 23, 2011 @ 12:50AMBiotechnology industry leaders want to speed up the process of bringing drugs to market by broadening the mission of the Food and Drug Administration, the federal agency that reviews new medicines, to include innovation as well as product safety.
- ‘Gene Patents’ Stifle Research? Tuesday, June 21, 2011 @ 12:22PMThe Federal Trade Commission has noted that “concern previously centered on the belief that biotechnology patent protection was too strong” and “would actually obstruct commercialization on new products, thereby hindering follow-on innovation. This problem has yet to materialize. The reasons for this are numerous and are often straightforward matters of basic economics. In addition to licensing ...
- LOEB & LOEB EXPANDS NATIONAL PATENT LITIGATION PRACTICE Monday, June 20, 2011 @ 11:27PMNEW YORK, June 20, 2011 – Loeb & Loeb LLP announced today that John M. Griem, Jr., will join the firm’s New York office as a partner in the Patent Litigation Practice. He joins from the New York office of Milbank, Tweed, Hadley & McCloy LLP where he was also a partner.
- DNA tool gives Phthisis Diagnostics success to build on Monday, June 20, 2011 @ 5:46PMPhthisis Diagnostics’ new product, the E-Sphere stool DNA extraction kit, allows laboratories to perform tests quicker and easier for certain molecules.
- Government of Canada Supports Innovation in Kingston Friday, June 17, 2011 @ 1:53PMKINGSTON, ONTARIO--(Marketwire - June 17, 2011) - Businesses in manufacturing, engineering and life sciences will have an opportunity to bring new products to market, expand and create new jobs thanks to a new partnership with Queen's University. Member of Parliament Gord Brown, on behalf of the Honourable Gary Goodyear, Minister of State for the Federal Economic Development Agency for Southern ...
- Gov. Robert Bentley takes part in latest HudsonAlpha groundbreaking Wednesday, June 15, 2011 @ 5:25PMBentley said the state has committed $10 million to the building, which will cover the cost of the facility before up to 10 tenants occupy it. The tenants will then finance any needed upgrades.
- Affymetrix Expands the Expression Power of the GeneAtlas® Personal Microarray System Tuesday, June 14, 2011 @ 5:26AMAffymetrix, Inc. (NASDAQ:AFFX) today announced the availability of the most widely cited gene expression microarray for use on the GeneAtlas ® ...
- Henri Termeer Joins Verastem Board of Directors Monday, June 13, 2011 @ 3:13PMCAMBRIDGE, Mass.--(BUSINESS WIRE)--Verastem, Inc., a biopharmaceutical company focused on discoverin...
- Paragon Bioservices to Partner and Exhibit at the 2011 BIO International Convention Thursday, June 9, 2011 @ 9:55AMParagon Bioservices, Inc., a Baltimore-based contract research and GMP manufacturing organization, announced today that representatives from the company will be participating in the 2011 BIO International Convention's One-on-One Partnering Meetings being held on June 27-30 in Washington, D.C. at the Walter E.
- Pfizer joins academics in bid for progress Thursday, June 9, 2011 @ 7:46AMPharmaceutical giant Pfizer Inc. announced an unusual partnership with leading Boston-area hospitals, medical schools, and universities yesterday, in an attempt to address a major problem in medicine: the years-long gap between basic science discoveries and the testing of drugs stemming from those advances.
- BioMed Realty Trust and Pfizer Sign New Lease at the Center for Life Science | Boston Wednesday, June 8, 2011 @ 1:00PMBioMed Realty Trust, Inc. announced today the signing of a new ten-year lease at the Center for Life Science | Boston with Pfizer Inc. , the world's leading biopharmaceutical company.
- Pfizer investing $100m in novel Boston research partnership Wednesday, June 8, 2011 @ 12:59PMBy Carolyn Y. Johnson, Globe Staff Pharmaceutical giant Pfizer Inc. will announce this afternoon a partnership with leading Boston-area hospitals,...
- A New Frontier Tuesday, June 7, 2011 @ 8:20AMNo Related Stories at this time! Dr. Pedro Huertas, a physician-turned biotechnology manager, is at the forefront of one of the most talked-about – and controversial – frontiers of medicine.
- Research and Markets: The World's Health Care Crisis. From the Laboratory Bench to the Patient's Bedside Thursday, June 2, 2011 @ 11:38AMResearch and Markets has announced the addition of Elsevier Science and Technology's new report "The World's Health Care Crisis. From the Laboratory Bench to the Patient's Bedside" to their offering.
- Tripos Announces Agios Pharmaceuticals’ Choice of D360 Software Wednesday, June 1, 2011 @ 8:33AMST. LOUIS--(BUSINESS WIRE)--Tripos welcomes Agios to the growing family of D360 customers; Agios has selected D360 for data integration, data mining, data visualization, and data analysis.
- Professor Noreen Murray: Scientist whose work paved the way for genetic engineering Tuesday, May 31, 2011 @ 6:22PMNoreen Murray was recognised internationally as being one of Britain's most distinguished and highly respected molecular geneticists.
- Cancer Research UK Signs Deal With Centella Therapeutics, Inc. to Launch Clinical Development of Radiotherapy ... Wednesday, May 25, 2011 @ 7:00AMCancer Research UK and Cancer Research Technology - the charity's development and commercialisation arm â have partnered with Centella Therapeutics, Inc. of Palo Alto, California, to develop, manufacture and trial a promising new drug, CEN-209 in cancer patients with solid tumours. Â
- Can Citizen Scientists Make Biotech More Efficient? Tuesday, May 24, 2011 @ 10:13AMThe vaccine for swine flu—better known as the H1N1 virus—relies on a rather ineffecient process. It involves raising chicken eggs in a clandestine network of farms—a so-called " feathered Manhattan Project "—then infecting the eggs and incubating them. The chicken and the eggs both get destroyed. What if amateurs had a hand in creating a better biotechnology? In Marcus Wohlsen's new book ...
- Biopunks Tinker With The Building Blocks Of Life Sunday, May 22, 2011 @ 4:09PMJournalist Marcus Wohlsen's new book explores the world of biopunks — amateur biotechnologists who believe science should be available to all, not confined to universities and corporate labs.
- Study Determined Best Dose And Showed 55 Percent Response Rate With Lilly Anti-BAFF Monoclonal Antibody In Previously ... Friday, May 20, 2011 @ 12:59AMEli Lilly and Company announced Phase I data on LY2127399, a human monoclonal antibody that neutralizes B-cell activating factor (BAFF), for use in combination with bortezomib in patients with previously-treated multiple myeloma.
- PBS Biotech® Launches Single-Use Bioreactor for Development of New Vaccines and Biosimilars Thursday, May 12, 2011 @ 8:45AMPBS Biotech, Inc., a developer of state of the art bioreactors to be used in the fast growing biotechnology market, announced today the launch of its innovative PBS 3 single-use bioreactor system.
- PBS Biotech® Launches Single-Use Bioreactor for Development of New Vaccines and Biosimilars Thursday, May 12, 2011 @ 8:45AMPBS Biotech, Inc., a developer of state of the art bioreactors to be used in the fast growing biotechnology market, announced today the launch of its innovative PBS 3 single-use bioreactor system.
- Stradling Adds Prominent Southern California Intellectual Property Litigator as Shareholder Monday, May 9, 2011 @ 5:43PMNEWPORT BEACH, Calif. & SAN DIEGO--(BUSINESS WIRE)--Stradling Hires Prominent IP Litigator as Shareholder. Alexandra (“Alex”) Mahaney, an IP litigation shareholder has joined Stradling Yocca Carlson & Rauth as a Shareholder, in its San Diego office.
- Pharmaceutical Litigation Partner James Stronski Joins Crowell & Moring Wednesday, May 4, 2011 @ 1:41PMWASHINGTON -- Crowell & Moring LLP is pleased to announce the addition of partner James K. Stron...
- Barclays, JPMorgan, Citigroup, Satyam-PwC, Actelion, Starr in Court News Tuesday, May 3, 2011 @ 5:58AMRaj Rajaratnam, the Galleon Group LLC co-founder, missed court after getting emergency surgery, and the jury weighing insider-trading charges against him will take today off for a juror’s medical procedure.
- In Print Tuesday, May 3, 2011 @ 1:50AMJournal: American Journal of Human Genetics . 2011 Apr 8;88(4):458-68. Title: A genome-wide comparison of the functional properties of rare and common genetic variants in humans.
- Life Technologies Announces First Quarter 2011 Results Tuesday, April 26, 2011 @ 3:02PMLife Technologies Corporation today announced results for its first quarter ending March 31, 2011. Non-GAAP revenue for the first quarter was $897 million, an increase of 1 percent over the $887 million reported for the first quarter of 2010.
- Portable PCR System features battery-powered operation. Monday, April 25, 2011 @ 8:19AMMeasuring 2.8 x 4.76 x 1.85 in., Palm PCR System delivers nucleic acid amplification in small handheld format. Unit includes fully validated operation protocols, PCR reagents and consumables, and matching accessories. Designed to conform to standard 9 mm-spaced well format for use with disposable plastic sample tube, system provides more than 4 hours of continuous operation on single battery ...
- Biomagnetics and Los Alamos National Laboratory Agreement Produce Validated Assay for Tuberculosis Biomarker - Company ... Wednesday, April 20, 2011 @ 8:14AMSAN FRANCISCO--(BUSINESS WIRE)--Biomagnetics Diagnostics Corp., (PINK SHEETS: BMGP) a developer of revolutionary diagnostic systems and related technology for detecting HIV, hepatitis, tuberculosis, cholera and malaria, and other innovative technologies, today announced it has now completed a series of payments to Los Alamos National Laboratory (LANL) pursuant to the cooperative research and ...
- Ahram Biosystems Announces Launch of the Palm PCR(TM) Portable PCR System Monday, April 18, 2011 @ 7:00AMAhram Biosystems, Inc., a leading innovator of new life science tools, today announced the launch of the Palm PCR system, an innovative portable PCR device that delivers high performance nucleic acid amplification in a small handheld format.
- Avacta Group PLC - Interim Results Monday, April 18, 2011 @ 1:10AMAvacta Group PLC - Interim Results
- UM: First Clinical Trial of Gene Therapy Shows Promise In Easing Pain Tuesday, April 12, 2011 @ 5:48PMIn the first clinical trial of gene therapy for treatment of intractable pain, researchers from the University of Michigan Department of Neurology observed that the treatment appears to provide substantial pain relief.
- First Clinical Trial Of Gene Therapy For Pain Reported By Neurologists Tuesday, April 12, 2011 @ 3:20AMIn the first clinical trial of gene therapy for treatment of intractable pain, researchers from the University of Michigan Department of Neurology observed that the treatment that appears to provide substantial pain relief. In a study published online in the Annals of Neurology last week, the researchers showed that the novel agent NP2 is safe and well-tolerated. In addition, measures of pain in ...
- First Clinical Trial Of Gene Therapy For Pain Monday, April 11, 2011 @ 11:18PMNew study suggests treatment may provide substantial relief In the first clinical trial of gene therapy for treatment of intractable pain, researchers from the University of Michigan Department of Neurology observed that the treatment appears to provide substantial pain relief. In a study published online in the Annals of Neurology last week, the researchers showed that the novel agent NP2 is ...
- First clinical trial of gene therapy for pain shows substantial pain relief for patients Monday, April 11, 2011 @ 11:16PMIn the first clinical trial of gene therapy for treatment of intractable pain, researchers observed that the treatment appears to provide substantial pain relief.
- First Clinical Trial of Gene Therapy for Pain Reported by U-M Neurologists Monday, April 11, 2011 @ 6:16PMNew study suggests treatment may provide substantial relief ANN ARBOR, Mich., April 11, 2011 /PRNewswire-USNewswire/ -- In the first clinical trial of gene therapy for treatment of intractable pain, researchers from the University of Michigan Department of Neurology observed that the treatment appears to provide substantial pain relief. In a study published online in the Annals of Neurology last ...
- First Clinical Trial of Gene Therapy for Pain Reported by Neurologists Monday, April 11, 2011 @ 3:42PMIn the first clinical trial of gene therapy for treatment of intractable pain, researchers from the University of Michigan Department of Neurology observed that the treatment that appears to provide substantial pain relief.
- First Clinical Trial of Gene Therapy for Pain Reported by U-M Neurologists Monday, April 11, 2011 @ 3:11PMNew study suggests treatment may provide substantial relief
- Ex-judge and Liberal hopeful apologizes for sex assault remarks Thursday, April 7, 2011 @ 2:07PMAn Alberta federal Liberal hopeful said sorry Thursday after making controversial comments on sexual assault on a radio show last week.[...]
